...
首页> 外文期刊>Diabetes therapy >Aspirin Versus Clopidogrel Monotherapy for the Secondary Prevention of Recurrent Cerebrovascular Attack Following Previous Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
【24h】

Aspirin Versus Clopidogrel Monotherapy for the Secondary Prevention of Recurrent Cerebrovascular Attack Following Previous Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

机译:阿司匹林与氯吡格雷单疗法为二次防止复发性脑血管病患者在患有2型糖尿病患者中缺血性脑卒中的二级预防:系统审查和荟萃分析

获取原文
           

摘要

IntroductionType 2 diabetes mellitus (T2DM) and stroke are two different diseases, but have many aspects in common. Aspirin is recommended as an initial treatment for the secondary prevention of recurrent ischemic stroke in patients with T2DM. However, clopidogrel is an oral antiplatelet drug that might be another choice in case of aspirin intolerance. In this analysis, we aimed to systematically compare aspirin versus clopidogrel monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM.MethodsOnline medical databases including Web of Science, MEDLINE, Cochrane central, EMBASE and http://www.ClinicalTrials.com were searched for published articles that satisfied the inclusion and exclusion criteria of this study. Recurrent stroke, fatal stroke, cerebral hemorrhage, myocardial infarction and mortality were considered the main end points in these patients with T2DM. RevMan 5.3 software was used to statistically analyze the data representing each subgroup. Risk ratios (RRs) with 95% confidence intervals (CIs) were used to represent the results following analysis.ResultsA total of 9218 participants with T2DM who were previously affected by ischemic stroke were included in this analysis, whereby 4917 were assigned to aspirin and 4301 to clopidogrel. This current analysis showed that there was no significant difference in recurrent stroke rate (RR: 0.79, 95% CI: 0.61–1.02; P =?0.07) observed with aspirin versus clopidogrel in these patients with T2DM. The risk of fatal stroke (RR: 0.88, 95% CI: 0.39–1.98; P =?0.76), cerebral hemorrhage (RR: 0.65, 95% CI: 0.38–1.11; P =?0.12), myocardial infarction (RR: 0.88, 95% CI: 0.43–1.79; P =?0.71) and mortality (RR: 1.07, 95% CI: 0.90–1.27; P =?0.44) were also similarly manifested.ConclusionClopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM. Hence, clopidogrel or aspirin monotherapy is equally safe and effective in these patients with T2DM.
机译:引入型2糖尿病(T2DM)和中风是两种不同的疾病,但有许多共同的方面。 Aspirin建议作为初步治疗T2DM患者中反复性缺血性卒中的初步治疗方法。然而,氯吡格雷是一种口服抗血小板药物,在阿司匹林不容忍的情况下可能是另一种选择。在这种分析中,我们旨在系统地比较阿司匹林与氯吡格雷单一治疗,以便在T2DM的患者患者中缺血性脑卒中后进行复发性脑血管疾病的二次预防..在包括科学网站,Medline,Cochrane中央,EMBASE和HTTP:// WWW中的患者.ClinicalTrials.com被搜查了出版的文章,满足了本研究的包含和排除标准。复发性中风,致命中风,脑出血,心肌梗塞和死亡率被认为是这些T2DM患者的主要终点。 Revman 5.3软件用于统计分析代表每个子组的数据。具有95%置信区间(CIS)的风险比(RRS)用于代表分析后的结果。在该分析中包括以前受缺血性卒中影响的T2DM的9218名参与者的总和,从而将4917分配给阿司匹林和4301氯吡格雷。该目前的分析表明,在这些T2DM中,在本患者中观察到任何具有阿司匹林与氯吡格雷的复发性卒中率(RR:0.79,95%CI:0.61-1.02; p = 0.61-1.02; p = 0.61-1.02)。致命中风的风险(RR:0.88,95%CI:0.39-1.98; P = 0.76),脑出血(RR:0.65,95%CI:0.38-1.11; P = 0.12),心肌梗塞(RR: 0.88,95%CI:0.43-1.79; p = 0.71)和死亡率(RR:1.07,95%CI:0.90-1.27; p = 0.44)也同样表现出来。结论Clopidogrel单疗法既不低于阿司匹林单药治疗在T2DM患者之前预防先前缺血性脑卒中后复发性脑血管疾病的二次预防。因此,氯吡格雷或阿司匹林单疗法在这些T2DM患者中同样安全和有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号